Thomas Starkey
Overview
Explore the profile of Thomas Starkey including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
1289
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Appanna N, Mew R, Williams S, Starkey T, Patel G, Hudson L, et al.
Int J Cancer
. 2025 Mar;
PMID: 40062998
SARS-CoV-2 continues to spread across the world as a highly transmissible endemic disease. For many cancer patients, SARS-CoV-2 infection is unavoidable. It continues to disrupt cancer care, causing treatment delays...
2.
Starkey T, Ionescu M, Tilby M, Little M, Burke E, Fittall M, et al.
Sci Rep
. 2023 Jul;
13(1):11327.
PMID: 37491478
Patients with cancer are at increased risk of hospitalisation and mortality following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. However, the SARS-CoV-2 phenotype evolution in patients with cancer since...
3.
4.
Suribhatla R, Starkey T, Ionescu M, Pagliuca A, Richter A, Lee L
Br J Haematol
. 2023 Apr;
201(5):813-823.
PMID: 37006158
Immunocompromised patients, such as those with a haematological malignancy, are at higher risk of SARS-CoV-2 infection, severe outcomes and mortality. Tixagevimab/cilgavimab is a monoclonal antibody combination which binds to the...
5.
Lee L, Tilby M, Starkey T, Ionescu M, Burnett A, Hattersley R, et al.
JAMA Oncol
. 2022 Dec;
9(2):188-196.
PMID: 36547970
Importance: Accurate identification of patient groups with the lowest level of protection following COVID-19 vaccination is important to better target resources and interventions for the most vulnerable populations. It is...
6.
Al Hajji Y, Taylor H, Starkey T, Lee L, Tilby M
Br J Cancer
. 2022 Oct;
127(10):1827-1836.
PMID: 36224402
Background: Patients living with cancer are at a significantly increased risk of morbidity and mortality after infection with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). This systematic review aims to investigate...
7.
Lee L, Ionescu M, Starkey T, Little M, Tilby M, Tripathy A, et al.
Eur J Cancer
. 2022 Sep;
175:1-10.
PMID: 36084618
Purpose: People living with cancer and haematological malignancies are at an increased risk of hospitalisation and death following infection with acute respiratory syndrome coronavirus 2. Coronavirus third dose vaccine boosters...
8.
Lee L, Starkey T, Ionescu M, Little M, Tilby M, Tripathy A, et al.
Lancet Oncol
. 2022 May;
23(6):748-757.
PMID: 35617989
Background: People with cancer are at increased risk of hospitalisation and death following infection with SARS-CoV-2. Therefore, we aimed to conduct one of the first evaluations of vaccine effectiveness against...
9.
Mistry D, Wang J, Moeser M, Starkey T, Lee L
BMC Infect Dis
. 2021 Aug;
21(1):828.
PMID: 34407759
Background: Lateral flow devices (LFDs) are viral antigen tests for the detection of SARS-CoV-2 that produce a rapid result, are inexpensive and easy to operate. They have been advocated for...
10.
Demetriou P, Abu-Shah E, Valvo S, McCuaig S, Mayya V, Kvalvaag A, et al.
Nat Immunol
. 2020 Oct;
22(1):99.
PMID: 33122852
No abstract available.